Revelation Biosciences, Inc. – NASDAQ:REVB
Revelation Biosciences stock price today
Revelation Biosciences stock price monthly change
Revelation Biosciences stock price quarterly change
Revelation Biosciences stock price yearly change
Revelation Biosciences key metrics
Market Cap | 2.42M |
Enterprise value | N/A |
P/E | -0.02 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.53 |
PEG ratio | N/A |
EPS | -30.94 |
Revenue | N/A |
EBITDA | -9.42M |
Income | -8.96M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRevelation Biosciences stock price history
Revelation Biosciences stock forecast
Revelation Biosciences financial statements
| Jun 2023 | 0 | -1.44M | |
|---|---|---|---|
| Sep 2023 | 0 | -2.62M | |
| Dec 2023 | 37.57K | -2.20M | -5862.84% |
| Mar 2024 | 0 | -2.68M |
| Sep 2025 | 0 | -2.27M | |
|---|---|---|---|
| Oct 2025 | 0 | -1.90M | |
| Dec 2025 | 0 | -62.34M | |
| Dec 2025 | 0 | -1.63M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 16038838 | 4.62M | 28.83% |
|---|---|---|---|
| Sep 2023 | 14218520 | 5.39M | 37.98% |
| Dec 2023 | 12212609 | 5.56M | 45.57% |
| Mar 2024 | 14701610 | 5.22M | 35.56% |
| Jun 2023 | -1.99M | 0 | 15 |
|---|---|---|---|
| Sep 2023 | -1.71M | 0 | 0 |
| Dec 2023 | -2.00M | 0 | 0 |
| Mar 2024 | -2.83M | -19.17K | 5.41M |
Revelation Biosciences alternative data
| Aug 2023 | 6 |
|---|---|
| Sep 2023 | 6 |
| Oct 2023 | 6 |
| Nov 2023 | 6 |
| Dec 2023 | 6 |
| Jan 2024 | 6 |
| Feb 2024 | 6 |
| Mar 2024 | 9 |
| Apr 2024 | 9 |
| May 2024 | 9 |
| Jun 2024 | 9 |
| Jul 2024 | 9 |
Revelation Biosciences other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 51500 | 0 |
| Sep 2023 | 0 | 26929 |
| Oct 2023 | 0 | 12802 |
| Dec 2023 | 0 | 27771 |
-
What's the price of Revelation Biosciences stock today?
One share of Revelation Biosciences stock can currently be purchased for approximately $2.63.
-
When is Revelation Biosciences's next earnings date?
Unfortunately, Revelation Biosciences's (REVB) next earnings date is currently unknown.
-
Does Revelation Biosciences pay dividends?
No, Revelation Biosciences does not pay dividends.
-
How much money does Revelation Biosciences make?
Revelation Biosciences has a market capitalization of 2.42M.
-
What is Revelation Biosciences's stock symbol?
Revelation Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "REVB".
-
What is Revelation Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Revelation Biosciences?
Shares of Revelation Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Revelation Biosciences have?
As Jul 2024, Revelation Biosciences employs 9 workers.
-
When Revelation Biosciences went public?
Revelation Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 17 Nov 2020.
-
What is Revelation Biosciences's official website?
The official website for Revelation Biosciences is revbiosciences.com.
-
Where are Revelation Biosciences's headquarters?
Revelation Biosciences is headquartered at 4660 La Jolla Village Drive, San Diego, CA.
-
How can i contact Revelation Biosciences?
Revelation Biosciences's mailing address is 4660 La Jolla Village Drive, San Diego, CA and company can be reached via phone at +65 08003717.
Revelation Biosciences company profile:
Revelation Biosciences, Inc.
revbiosciences.comNASDAQ
9
Biotechnology
Healthcare
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
San Diego, CA 92122
CIK: 0001810560
ISIN: US76135L5075
CUSIP: 76135L101
